A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

被引：0

作者：

Terpos, Evangelos ^{[1
]}

Kastritis, Efstathios ^{[2
]}

Symeonidis, Argiris ^{[3
]}

Pouli, Anastasia ^{[4
]}

Delimpasi, Sosana ^{[5
]}

Katodritou, Eirini ^{[6
]}

Hatzimichael, Eleftheria ^{[7
]}

Ntanasis-Stathopoulos, Ioannis ^{[8
]}

Malandrakis, Panagiotis ^{[8
]}

Fotiou, Despina ^{[8
]}

Migkou, Magdalini ^{[8
]}

Theodorakakou, Foteini ^{[8
]}

Spiliopoulou, Vasiliki ^{[8
]}

Syrigou, Rodanthi ^{[8
]}

Eleutherakis-Papaiakovou, Evangelos ^{[2
]}

Manousou, Kyriaki ^{[9
]}

Gavriatopoulou, Maria

Dimopoulos, Meletios A. ^{[2
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Drosia, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] Univ Patras, Sch Med, Hematol Div, Dept Internal Med, Patras, Greece

[4] St Savvas Oncol Hosp, Hematol Dept, Athens, Greece

[5] Gen Hosp Evangelismos, Athens, Greece

[6] Theagenio Canc Hosp, Dept Hematol, Thessaloniki, Greece

[7] Univ Ioannina, Dept Hematol, Fac Med, Ioannina, Greece

[8] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[9] Hlth Data Specialists, Dublin, Ireland

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial [J].

Goldschmidt, Hartmut ;

Mai, Elias K. ;

Nievergall, Eva ;

Fenk, Roland ;

Bertsch, Uta ;

Tichy, Diana ;

Besemer, Britta ;

Duerig, Jan ;

Schroers, Roland ;

Metzler, Ivana V. ;

Haenel, Mathias ;

Mann, Christoph ;

Asemissen, Anne-Marie ;

Heilmeier, Bernhard ;

Huhn, Stefanie ;

Kriegsmann, Katharina ;

Weinhold, Niels ;

Luntz, Steffen P. ;

Holderried, Tobias A. W. ;

Trautmann-Grill, Karolin ;

Gezer, Deniz ;

Klaiber-Hakimi, Maika ;

Mueller, Martin ;

Khandanpour, Cyrus ;

Knauf, Wolfgang ;

Munder, Markus ;

Geer, Thomas ;

Riesenberg, Hendrik ;

Thomalla, Joerg ;

Hoffmann, Martin ;

Raab, Marc-Steffen ;

Salwender, Hans ;

Weisel, Katja .

BLOOD, 2021, 138

[32] A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma [J].

Becker, P. S. ;

Gooley, T. A. ;

Green, D. J. ;

Burwick, N. ;

Kim, T. Y. ;

Kojouri, K. ;

Inoue, Y. ;

Moore, D. J. ;

Nelli, E. ;

Dennie, T. ;

Bensinger, W. I. .

BLOOD CANCER JOURNAL, 2016, 6 :e422-e422

[33] A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma [J].

P S Becker ;

T A Gooley ;

D J Green ;

N Burwick ;

T Y Kim ;

K Kojouri ;

Y Inoue ;

D J Moore ;

E Nelli ;

T Dennie ;

W I Bensinger .

Blood Cancer Journal, 2016, 6 :e422-e422

[34] A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM) [J].

Khan, M. L. ;

Reeder, C. B. ;

Kumar, S. ;

Lacy, M. ;

Reece, D. E. ;

Laumann, K. M. ;

Mikhael, J. ;

Fonseca, R. ;

Rajkumar, V. ;

Stewart, A. K. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[35] Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). [J].

Orlowski, Robert Z. ;

Goldschmidt, Hartmut ;

Cavo, Michele ;

Martin, Thomas G. ;

Paux, Gautier ;

Oprea, Corina ;

Facon, Thierry .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[36] Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma [J].

O'Gorman, Peter ;

Laubach, Jacob P. ;

O'Dwyer, Michael E. ;

Krawczyk, Janusz ;

Yee, Andrew J. ;

Gilligan, Oonagh ;

Cahill, Mary R. ;

Rosenblatt, Jacalyn ;

Quinn, John ;

Murphy, Philip T. ;

DiPietro, Heidi ;

Perera, Meegahage Ratnakanthi ;

Crotty, Gerard M. ;

Cummings, Kristen ;

Hayden, Patrick J. ;

Browne, Paul ;

Savell, Alexandra ;

O'Leary, Hilary M. ;

O'Keeffe, Denis ;

Masone, Kelly ;

Hennessy, Brian J. ;

Garcia, Thomas Guerrero ;

Scott, Kathleen ;

Saeed, Khalid ;

Bianchi, Giada ;

Dowling, Paul ;

Tierney, Ciara ;

Richardson, Paul G. .

AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) :562-573

[37] Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis [J].

An, Gang ;

Liu, Zhuogang ;

Jin, Jie ;

Cai, Zhen ;

Li, Wei ;

Xia, Zhongjun ;

Cen, Xinan ;

Hu, Yu ;

Mi, Jian-Qing ;

Jing, Hongmei ;

Zhan, Rong ;

Qu, Xiaoyan ;

Du, Xin ;

Gao, Dan ;

Zhao, Liang ;

Qiu, Lugui .

BLOOD, 2024, 144 :7055-7056

[38] Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial [J].

Askeland, Frida Bugge ;

Haukas, Einar ;

Slordahl, Tobias S. ;

Klostergaard, Anja ;

Alexandersen, Tatjana ;

Lysen, Anna ;

Abdollahi, Pegah ;

Nielsen, Lene Kongsgaard ;

Hermansen, Emil ;

Schjesvold, Fredrik .

LANCET HAEMATOLOGY, 2025, 12 (02) :e120-e127

[39] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma [J].

Martin, Thomas ;

Baz, Rachid ;

Benson, Don M. ;

Lendvai, Nikoletta ;

Wolf, Jeffrey ;

Munster, Pamela ;

Lesokhin, Alexander M. ;

Wack, Claudine ;

Charpentier, Eric ;

Campana, Frank ;

Vij, Ravi .

BLOOD, 2017, 129 (25) :3294-3303

[40] Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5) [J].

Dytfeld, Dominik ;

Dhakal, Binod ;

Agha, Mounzer ;

Manier, Salomon ;

Delforge, Michel ;

Kuppens, Steven ;

Afifi, Salma ;

Deraedt, William ;

Taraseviciute-Morris, Agne ;

Schecter, Jordan M. ;

Gilbert, Jane ;

Yalniz, Fevzi ;

Florendo, Erika ;

Pacaud, Lida ;

Hungria, Vania ;

Usmani, Saad Z. ;

Mateos, Maria-Victoria .

BLOOD, 2021, 138 :1835-+

← 1 2 3 4 5 →